11.04.2013 - Fuelled by €1.1m of EU money, six European partners from industry and academia plan to find kinase-targeting drugs in a venture called TAKTIC.
A focussed group of three SMEs and three academic partners form the Translational Kinase Tumour Inhibitor Discovery Consortium (TAKTIC). Members announced on 10 April the creation of the consortium which is financed to the tune of €1.1m by the EU’s 7th Framework Programme “Research for the Benefit of SMEs”. The industry partners comprise SARomics Biostructures from Lund (Sweden), Prestwick Chemical from Illkirch (France) and ProQinase GmbH from Freiburg (Germany). The collaborating academic scientists work at the University of Turin (Italy) the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science and the TechMedIll platform of the University of Strasbourg (France).
Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium offers its members extensive expertise in medicinal chemistry, kinase biochemistry as well as state-of-the-art high-throughput platforms for protein expression and crystallisation. The merging of the highly complementary capabilities of the six partners within TAKTIC enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases, the partners said in a joint press release.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.